Pharmacokinetics of intranasal drugs, still a missed opportunity?

被引:1
作者
Sardu, Maria Luisa [1 ]
Poggesi, Italo [2 ]
机构
[1] UCB Pharm SPA, Milan, Italy
[2] GSK, Clin Pharmacol Modeling & Simulat, Verona, Italy
关键词
Intranasal; pharmacokinetics; administration route; nose-to-brain; modelling; TO-BRAIN DELIVERY; DIRECT NOSE; NASAL ROUTE; SYSTEM; NANOPARTICLES; NANOEMULSION; TRANSPORT; BIOAVAILABILITY; PHYSIOLOGY; RATS;
D O I
10.1080/00498254.2024.2349046
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The intranasal (IN) route of administration is important for topical drugs and drugs intended to act systemically. More recently, direct nose-to-brain input was considered to bypass the blood-brain barrier.Processes related to IN absorption and nose-to-brain distribution are complex and depend, sometimes in contrasting ways, on chemico-physical and structural parameters of the compounds, and on formulation options.Due to the intricacies of these processes and despite the large number of articles published on many different IN compounds, it appears that absorption after IN dosing is not yet fully understood. In particular, at variance of the understanding and modelling approaches that are available for predicting the pharmacokinetics (PK) following oral administration of xenobiotics, it appears that there is not a similar understanding of the chemico-physical and structural determinants influencing drug absorption and disposition of compounds after IN administration, which represents a missed opportunity for this research field. This is even more true regarding the understanding of the direct nose-to-brain input. Due to this, IN administrations may represent an interesting and open research field for scientists aiming to develop PK property predictions tools, mechanistic PK models describing rate and extent of IN absorption, and translational tools to anticipate the clinical PK following IN dosing based on in vitro and in vivo non clinical experiments.This review intends to provide: i) some basic knowledge related to the physiology of PK after IN dosing, ii) a non-exhaustive list of preclinical and clinical examples related to compounds explored for the potential nose-to-blood and nose-to-brain passage, and iii) the identification of some areas requiring improvements, the understanding of which may facilitate the development of IN drug candidates.
引用
收藏
页码:424 / 438
页数:15
相关论文
共 92 条
[61]   Brain-Targeted Intranasal Delivery of Zotepine Microemulsion: Pharmacokinetics and Pharmacodynamics [J].
Pailla, Sravanthi Reddy ;
Sampathi, Sunitha ;
Junnuthula, Vijayabhaskarreddy ;
Maddukuri, Sravya ;
Dodoala, Sujatha ;
Dyawanapelly, Sathish .
PHARMACEUTICS, 2022, 14 (05)
[62]   Nose-to-Brain delivery of donepezil hydrochloride following administration of an HPMC-Me-β-CD-PEG400 nasal film in mice [J].
Papakyriakopoulou, Paraskevi ;
Balafas, Evangelos ;
Colombo, Gaia ;
Rekkas, Dimitrios M. ;
Kostomitsopoulos, Nikolaos ;
Valsami, Georgia .
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 2023, 84
[63]  
Parrott N., 2016, Oral drug absorption: prediction and assessment. 2nd ed, P354
[64]   Nasal Administration and Plasma Pharmacokinetics of Parathyroid Hormone Peptide PTH 1-34 for the Treatment of Osteoporosis [J].
Pearson, Richard G. ;
Masud, Tahir ;
Blackshaw, Elaine ;
Naylor, Andrew ;
Hinchcliffe, Michael ;
Jeffery, Kirk ;
Jordan, Faron ;
Shabir-Ahmed, Anjumn ;
King, Gareth ;
Lewis, Andrew L. ;
Illum, Lisbeth ;
Perkins, Alan C. .
PHARMACEUTICS, 2019, 11 (06)
[65]   Comparative pharmacokinetics of single doses of doxylamine succinate following intranasal, oral and intravenous administration in rats [J].
Pelser, A ;
Müller, DG ;
du Plessis, J ;
du Preez, JL ;
Goosen, C .
BIOPHARMACEUTICS & DRUG DISPOSITION, 2002, 23 (06) :239-244
[66]   Population Pharmacokinetics of Esketamine Nasal Spray and its Metabolite Noresketamine in Healthy Subjects and Patients with Treatment-Resistant Depression [J].
Perez-Ruixo, Carlos ;
Rossenu, Stefaan ;
Zannikos, Peter ;
Nandy, Partha ;
Singh, Jaskaran ;
Drevets, Wayne C. ;
Perez-Ruixo, Juan Jose .
CLINICAL PHARMACOKINETICS, 2021, 60 (04) :501-516
[67]   Intranasal Drug Delivery: How, Why and What for? [J].
Pires, Anaisa ;
Fortuna, Ana ;
Alves, Gilberto ;
Falcao, Amilcar .
JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, 2009, 12 (03) :288-311
[68]   Advances in the field of intranasal oxytocin research: lessons learned and future directions for clinical research [J].
Quintana, Daniel S. ;
Lischke, Alexander ;
Grace, Sally ;
Scheele, Dirk ;
Ma, Yina ;
Becker, Benjamin .
MOLECULAR PSYCHIATRY, 2021, 26 (01) :80-91
[69]   Selective CNS Uptake of the GCP-II Inhibitor 2-PMPA following Intranasal Administration [J].
Rais, Rana ;
Wozniak, Krystyna ;
Wu, Ying ;
Niwa, Minae ;
Stathis, Marigo ;
Alt, Jesse ;
Giroux, Marc ;
Sawa, Akira ;
Rojas, Camilo ;
Slusher, Barbara S. .
PLOS ONE, 2015, 10 (07) :e0131861
[70]   Intranasal Coadministration of a Diazepam Prodrug with a Converting Enzyme Results in Rapid Absorption of Diazepam in Rats [J].
Rautiola, Davin ;
Maglalang, Patricia D. ;
Cheryala, Narsihmulu ;
Nelson, Kathryn M. ;
Georg, Gunda, I ;
Fine, Jared M. ;
Svitak, Aleta L. ;
Faltesek, Katherine A. ;
Hanson, Leah R. ;
Mishra, Usha ;
Coles, Lisa D. ;
Cloyd, James C. ;
Siegel, Ronald A. .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2019, 370 (03) :796-+